Literature DB >> 9261419

Cyclophilin A-induced alterations of human immunodeficiency virus type 1 CA protein in vitro.

B E Agresta1, C A Carter.   

Abstract

Cyclophilin A (CyP A), a cellular chaperone with cis-trans prolyl isomerase activity, is required for postassembly events in human immunodeficiency virus type 1 (HIV-1) replication. The requirement for CyP A maps to sequences in the capsid (CA) domain of the structural precursor, Gag. To determine the effects of interaction with CyP A on capsid (CA) protein structure, the binding interaction was investigated in vitro, using recombinant HIV-1 CA protein (which forms oligomers in solution) and human CyP A. The CA and CyP A proteins interacted to form a complex which was detected predominantly as a heterodimer on sodium dodecyl sulfate (SDS)-polyacrylamide gels. Complex formation exhibited a pH optimum of 5. The CA protein in the complex was exclusively in a conformation whereby the N terminus was blocked to Edman degradation. This finding was unexpected since CyP A binds to the central region of the CA protein (residues 85 to 93). Examination of CA protein incubated with CyP A for alterations in structure indicated that CyP A preferentially interacted with the subpopulation of trypsin-susceptible subunits in the oligomers and significantly reduced their sensitivity to proteolysis. Like CA-CyP A complex formation, conversion to trypsin resistance also exhibited a pH optimum of 5. Both complex formation and the changes in tryptic susceptibility were only partially inhibited by cyclosporin A (CsA). This appeared to be due to a CA subpopulation able to bind CyP A despite the presence of CsA. Our results identify specific tryptic sites both proximal and distal to the CyP A binding region that are altered by CyP A binding and/or by CyP A's prolyl isomerase activity. Comparison with the X-ray structure of a complex containing CyP A bound to an amino-terminal fragment of the CA protein (CA1-151) (T.R. Gamble et al., Cell 87:1285-1294, 1996) indicates that the tryptic sites that become inaccessible are among the same residues that lose a significant amount of accessible surface area through CA-CA subunit contacts made in the presence of CyP A.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261419      PMCID: PMC191975     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Cyclophilins: a new family of proteins involved in intracellular folding.

Authors:  M A Stamnes; S L Rutherford; C S Zuker
Journal:  Trends Cell Biol       Date:  1992-09       Impact factor: 20.808

Review 2.  Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction.

Authors:  C T Walsh; L D Zydowsky; F D McKeon
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

Review 3.  Immunophilins in protein folding and immunosuppression.

Authors:  D A Fruman; S J Burakoff; B E Bierer
Journal:  FASEB J       Date:  1994-04-01       Impact factor: 5.191

4.  Interactions of HIV-1 proteins with human T-cell cyclophilin A.

Authors:  F Hammerschmid; A Billich; E Wasserbauer; B Rosenwirth
Journal:  Ann N Y Acad Sci       Date:  1996-05-15       Impact factor: 5.691

5.  Crystal structure of dimeric HIV-1 capsid protein.

Authors:  C Momany; L C Kovari; A J Prongay; W Keller; R K Gitti; B M Lee; A E Gorbalenya; L Tong; J McClure; L S Ehrlich; M F Summers; C Carter; M G Rossmann
Journal:  Nat Struct Biol       Date:  1996-09

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.

Authors:  T Dorfman; H G Göttlinger
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

9.  Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase.

Authors:  B Steinmann; P Bruckner; A Superti-Furga
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

10.  Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.

Authors:  A Steinkasserer; R Harrison; A Billich; F Hammerschmid; G Werner; B Wolff; P Peichl; G Palfi; W Schnitzel; E Mlynar
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more
  10 in total

1.  CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A.

Authors:  T Pushkarsky; G Zybarth; L Dubrovsky; V Yurchenko; H Tang; H Guo; B Toole; B Sherry; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Authors:  L Dietrich; L S Ehrlich; T J LaGrassa; D Ebbets-Reed; C Carter
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Cryoelectron microscopic examination of human immunodeficiency virus type 1 virions with mutations in the cyclophilin A binding loop.

Authors:  L B Kong; D An; B Ackerson; J Canon; O Rey; I S Chen; P Krogstad; P L Stewart
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells.

Authors:  D Braaten; J Luban
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

5.  trans-Complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity.

Authors:  Andrew C S Saphire; Michael D Bobardt; Philippe A Gallay
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.

Authors:  Morgane Rolland; Mark A Jensen; David C Nickle; Jian Yan; Gerald H Learn; Laura Heath; David Weiner; James I Mullins
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

7.  Chimeric human immunodeficiency virus type 1 (HIV-1) virions containing HIV-2 or simian immunodeficiency virus Nef are resistant to cyclosporine treatment.

Authors:  Mahfuz Khan; Lingling Jin; Ming Bo Huang; Lesa Miles; Vincent C Bond; Michael D Powell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Treatment of human immunodeficiency virus type 1 virions depleted of cyclophilin A by natural endogenous reverse transcription restores infectivity.

Authors:  Mahfuz Khan; Minerva Garcia-Barrio; Michael D Powell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase.

Authors:  Shixing Tang; Tsutomu Murakami; Naiqian Cheng; Alasdair C Steven; Eric O Freed; Judith G Levin
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Suppression of feline coronavirus replication in vitro by cyclosporin A.

Authors:  Yoshikazu Tanaka; Yuka Sato; Shuichi Osawa; Mai Inoue; Satoka Tanaka; Takashi Sasaki
Journal:  Vet Res       Date:  2012-04-30       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.